Conference Day One

7:45 am Check-In & Light Breakfast

8:25 am Chair’s Opening Remarks

Creating Easy-to-Scale Projects to Become an Attractive Acquisition Prospect for Investors

8:30 am Navigating Investment Pathways for Startup Companies Within the Nasal Space

  • Ryan Kole Co-Founder, Beyond Barriers Therapeutics

Synopsis

  • Emphasis on presenting strong preclinical and early clinical data that demonstrate the safety, efficacy, and unique benefits of the intranasal drug, showcasing its potential for market success
  • Discussion of the importance of articulating a compelling value proposition that outlines the product’s competitive advantages, potential market impact, and alignment with current healthcare trends
  • Insights into building strategic partnerships with industry leaders and highlighting any existing funding or collaborations that enhance credibility

9:00 am Roundtable: Exploring Strategies Employed From Starting a Drug Company to Successful Exit

Synopsis

  • Overview of key initial steps in building a nasal drug company, including identifying niche markets, developing a unique value proposition, and securing initial funding
  • Effective strategies for navigating regulatory pathways and clinical trials specific to nasal drug delivery, ensuring compliance, and accelerating product development
  • Crafting a strategic exit plan, including identifying potential acquirers, forming partnerships with larger pharmaceutical companies, and positioning the company for maximum valuation at exit

9:30 am Talk Reserved For Silgan Dispensing

10:00 am Speed Networking

Synopsis

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get face-to-face time with many of the nasal formulation and delivery experts to establish meaningful business relationships.

10:30 am Morning Break & Networking

11:00 am Talk Reserved for Renaissance Lakewood

11:30 am Keep It Simple Stupid: Making Intranasal Biologic Drugs for Population Scale Access

  • Brian Finrow Founder & Chief Executive Officer, Lumen Bioscience

Synopsis

  • GMP scalability and COGS once made intranasal biologics impossible
  • New technology makes this feasible today, unlocking key advantages in development costs, commercial viability, and equitable access
  • How to think about optimally balancing the tradeoffs between safety, purity, and developability

12:00 pm Lunch & Networking

Increasing Drug Bioavailability in Target Regions to Maximize Drug Utility

1:00 pm Enhancing Bioavailability of Nasal Drugs to Maximise Drug Retention in the Brain

Synopsis

  • Discussion of innovative formulation approaches designed to facilitate direct drug transport to the brain while minimizing systemic absorption into the bloodstream
  • Examination of techniques to optimize the intranasal delivery route, including device design and administration protocols, to enhance localized drug retention
  • Ways to assess the distribution of drugs in the brain versus systemic circulation, guiding formulation adjustments to improve overall bioavailability and therapeutic efficacy

1:30 pm Talk Reserved for Aptar

2:00 pm Enhancing Bioavailability of Nasal Drugs to Maximize Drug Retention in Systemic Targets

Synopsis

  • Increase bioavailability and retention for targeted efficacy
  • Explore pathways to enhance systemic absorption
  • Strategies to reduce nasal clearance for sustained drug impact

2:30 pm Afternoon Break & Poster Session

Synopsis

Witness some of the latest and greatest research in the nasal drug development & delivery field by drug developers, academics, service providers, and researchers in this spotlight poster session!

3:00 pm Talk Reserved for Nemera

3:30 pm Bridging Pre-Clinical & Early Human Studies With Clinical Design

Synopsis

  • Case-study led insights on current clinical development program
  • Design of clinical trials and how this is linked back to delivery
  • Ways to optimize these methods

4:00 pm Chair’s Closing Remarks